
Nutra Pharma Announces the Submission of Their First Orphan Drug Application to the US Food and Drug
July 15, 2015 July 15, 2015 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have filed an application with the FDA for orphan drug status of the Company's RPI-78M drug candidate

SeeThruEquity Initiates Coverage on Nutra Pharma Corporation with a Price Target of $0.53
July 10, 2015 NEW YORK, NY / ACCESSWIRE / July 10, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Nutra Pharma Corporation (NPHC) with a Price Target of $0.53. The report is available here:http://www.seethruequity.com/#!nphc/c16dr NPHC Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ